Therefore, the use of CDK7 and CDK9 inhibitors in combination with immune checkpoint inhibitors may represent a powerful therapeutic combination, particularly for tumours displaying a “cold” immune microenvironment, as is the case of prostate cancer. Here, CDK9 is linked to neoplasm.